171722-92-2

Basic information

• Product Name: piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate
• Synonyms: piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate;piperidin-4-yl N-(2-phenylphenyl)carbamate;Carbamic acid, N-[1,1'-biphenyl]-2-yl-, 4-piperidinyl ester-;16403-A2 ,9291;4-PIPERIDYL N-(2-BIPHENYL)CARBAMATE
• CAS NO: 171722-92-2
• Molecular Formula: C₁₈H₂₀N₂O₂
• Molecular Weight: 296.3636
• EINECS: -0
• Mol File: 171722-92-2.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 427.053°C at 760 mmHg
• Flash Point: 212.075°C
• Appearance: /
• Density: 1.193g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.612
• PKA: 13.34±0.70(Predicted)
• CAS DataBase Reference: piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate(171722-92-2)
• EPA Substance Registry System: piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate(171722-92-2)

Safety Data

• Hazardous Substances Data: 171722-92-2(Hazardous Substances Data)

Usage

Physical Form

Solid

Uses

4-Piperidyl N-(2-biphenylyl)carbamate is an intermediate in the synthesis of Des-4''(methylpiperidine-4-carboxamide)-4''-hydroxymethyl Revefenacin (D119860), an impurity of Revefenacin (R279600). Revefenacin is a pharmaceutical drug for the treatment of chronic obstructive pulmonary diseases.

InChI:InChI=1/C18H20N2O2/c21-18(22-15-10-12-19-13-11-15)20-17-9-5-4-8-16(17)14-6-2-1-3-7-14/h1-9,15,19H,10-13H2,(H,20,21)

Upstream product

• 90-41-5 2-phenylaniline 
• 1225223-05-1 C₁₄H₂₁N₃O₄ 
• 17337-13-2 [1,1'-biphenyl]-2-yl-isocyanate 
• 171723-80-1 1-benzyl-4-piperidylbiphenyl-2-ylcarbamate 
• 4727-72-4 1-benzyl-4-hydroxypiperidine 
• 947-84-2 2-Biphenylcarboxylic acid 

Downstream Products

• 743461-40-7 biphenyl-2-ylcarbamic Acid 1-[2-Fluoro-3-(4-hydroxymethylpiperidin-1-ylmethyl)-benzyl]piperidin-4-yl Ester 
• 864686-28-2 biphenyl-2-yl-carbamic acid 1-[2-(benzylmethylamino)ethyl]piperidin-4-yl ester 
• 1309750-53-5 C₂₂H₂₈N₂O₃ 
• 743460-71-1 C₃₉H₅₃N₃O₅ 
• 743460-72-2 biphenyl-2-ylcarbamic acid 1-{9-[(R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethylamino]nonyl}piperidin-4-yl ester 
• 743460-16-4 biphenyl-2-ylcarbamic acid 1-{9-[2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]nonyl}piperidin-4-yl ester 
• 1309750-61-5 C₂₀H₂₂N₂O₃ 
• 1309750-62-6 C₂₁H₂₄N₂O₃ 
• 1309750-63-7 C₂₂H₂₆N₂O₃ 
• 1289178-38-6 C₃₄H₃₇N₃O₂ 
• 1289178-39-7 C₃₅H₃₉N₃O₂ 
• 1289178-40-0 C₃₆H₄₁N₃O₂ 
• 1289178-41-1 C₃₇H₄₃N₃O₂ 
• 1289178-42-2 C₃₈H₄₅N₃O₂ 

Relevant articles and documents

GSK961081 and its intermediate synthesis method

The invention relates to a new method for preparing a medicine GSK961081 and an intermediate thereof. Compared with an existing synthetic method, the new method not only avoids the use of a hypertoxic isocyanate reagent, but also is simple in synthetic ro

PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID

The invention provides a process of preparing an intermediate useful in the synthesis of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and a process of preparing a crystalline freebase of the ester.

Crystalline forms of a biphenyl compound

The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-[2-({3-[2-(4-hydroxybenzylamino)ethylcarbamoyl]benzoyl}methylamino)ethyl]piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase (Form I or II), a salt such as a hemiedisylate salt or a heminapadisylate salt, or a solvate of a salt such as a heminapadisylate methanolate or a heminapadisylate ethanolate. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.